Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. develops clinical-stage small molecule precision medicines for cancer and genetic disease. The company uses its Dynamo® platform, which combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed.
Recurring RLAY news centers on zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor studied in HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies. Company updates also cover pipeline programs for NRAS-driven solid tumors and Fabry disease, clinical and regulatory data presentations, operating results, capital-structure matters, license or collaboration agreements, and governance developments.
Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on February 9, 2023, at 10:10 a.m. ET. The event will be streamed live and accessible on their website under the Events section. An archived replay will be available for 30 days post-presentation.
Relay Therapeutics is a clinical-stage precision medicine company focused on enhancing drug discovery through its innovative Dynamo™ platform, targeting oncology and genetic diseases. This cutting-edge approach combines computational and experimental technologies to develop impactful therapies for patients.
Relay Therapeutics (Nasdaq: RLAY) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 2:15 p.m. PT. The event will be webcast live, accessible via Relay Therapeutics' website under the News & Events section. An archived version will be available for 30 days post-event. Relay Therapeutics is a clinical-stage precision medicine company, innovating drug discovery using its Dynamo™ platform to target challenging protein targets, focusing on oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) will participate in two key conferences in November 2022. The H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference is on November 14 at 10:00 a.m. ET, followed by the Stifel 2022 Healthcare Conference on November 16 at 1:15 p.m. ET. Both events will be accessible via live webcast on Relay Therapeutics' website, with archived replays available for 30 days post-presentation. Relay Therapeutics is a clinical-stage precision medicine company focusing on drug discovery using advanced technologies.
Relay Therapeutics reported strong interim results for RLY-4008, showing an 88% overall response rate among FGFR2-fusion cholangiocarcinoma patients at the ESMO Congress. This supports the potential of their Dynamo platform in developing therapies for FGFR2-driven tumors. The company also reported $1.1 billion in cash and equivalents, sufficient to fund operations into 2025. However, R&D expenses rose to $66.9 million, leading to a net loss of $84.2 million for Q3 2022. Relay continues to focus on advancing its clinical trials and therapies.
Relay Therapeutics (Nasdaq: RLAY) plans to release its third quarter 2022 financial results and corporate highlights on November 3, 2022, after market close. The company specializes in precision medicine, utilizing advanced computational and experimental technologies in drug discovery. Notably, it aims to tackle complex protein targets through its Dynamo™ platform. Notably, no teleconference will follow the financial results release.
Relay Therapeutics (Nasdaq: RLAY) is set to participate in a virtual fireside chat at the Bank of America Securities 2022 Precision Oncology Conference on October 3, 2022, at 2:50 p.m. ET. The event will be webcast live and can be accessed via Relay Therapeutics’ website. An archived replay will be available for up to 30 days after the presentation. Relay Therapeutics focuses on transforming drug discovery using its Dynamo™ platform, aimed at enhancing small molecule therapeutic discovery in oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) announced a public offering of 11,320,755 shares at $26.50 each, aiming to raise approximately $300 million before expenses. An additional 1,698,113 shares may be purchased by underwriters within 30 days. The offering, managed by Goldman Sachs, J.P. Morgan, and Cowen, is set to close around September 15, 2022. This financing effort is part of Relay's strategy to enhance drug discovery capabilities, focusing on targeted oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) has announced a public offering of $300 million in common stock, with an option for underwriters to buy an additional 15%. This offering is part of a strategy to enhance its capital position for advancing its precision medicine initiatives in drug discovery. The proposed shares are being sold solely by Relay Therapeutics and will be offered under an effective shelf registration statement previously filed with the SEC. Major banks involved include Goldman Sachs, J.P. Morgan, and Cowen.
Relay Therapeutics (Nasdaq: RLAY) has announced a collaboration with Foundation Medicine to develop FoundationOne®CDx as a companion diagnostic for RLY-4008, an investigational FGFR2 inhibitor targeting cholangiocarcinoma. Interim clinical data presented at ESMO 2022 showed an 88% overall response rate in patients with FGFR2 mutations. The partnership aims to enable more effective treatments for patients with aggressive conditions, expanding access to precision medicine.
Relay Therapeutics (Nasdaq: RLAY) announced promising interim clinical results for RLY-4008, a selective FGFR2 inhibitor, achieving an 88% overall response rate in FGFRi-naïve FGFR2-fusion cholangiocarcinoma patients. Data were presented at the ESMO Congress, reflecting results from 17 patients as of August 1, 2022. The pivotal cohort enrollment is expected to wrap up in the second half of 2023. The company is also gearing up to reveal further data on RLY-2608, a pan-mutant selective PI3Kα inhibitor, within the next year.